The COPD Pipeline XXXII.
作者信息
Gross Nicholas
机构信息
Emeritus Professor of Medicine and Molecular Biology, Stritch-Loyola School of Medicine, Chicago, Illinois.
出版信息
Chronic Obstr Pulm Dis. 2016 Jul 14;3(3):688-692. doi: 10.15326/jcopdf.3.3.2016.0150.
Abstract
摘要
相似文献
1
The COPD Pipeline XXXII.慢性阻塞性肺疾病研发管线XXXII。
Chronic Obstr Pulm Dis. 2016 Jul 14;3(3):688-692. doi: 10.15326/jcopdf.3.3.2016.0150.
2
The COPD Pipeline XXIX.慢性阻塞性肺疾病（COPD）研发管线二十九。
Chronic Obstr Pulm Dis. 2015 Oct 20;2(4):370-374. doi: 10.15326/jcopdf.2.4.2015.0163.
3
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.AZD7624用于预防慢性阻塞性肺疾病急性加重的研究：一项随机对照试验。
Int J Chron Obstruct Pulmon Dis. 2018 Mar 27;13:1009-1019. doi: 10.2147/COPD.S150576. eCollection 2018.
4
Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.正在开发用于治疗 COPD 的吸入型 PI3Kδ 抑制剂 GSK2269557 的安全性、药代动力学和剂量反应特征。
Pulm Pharmacol Ther. 2017 Oct;46:69-77. doi: 10.1016/j.pupt.2017.08.008. Epub 2017 Aug 17.
5
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-659-泰泽卡托维伐替卡与依伐卡托维在携带一个或两个 Phe508del 等位基因的囊性纤维化患者中的疗效。
N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.
6
The COPD Pipeline XXX.慢性阻塞性肺疾病研发管线XXX。
Chronic Obstr Pulm Dis. 2015 Dec 14;3(1):498-502. doi: 10.15326/jcopdf.3.1.2015.0181.
7
Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?在大鼠腓骨截骨模型中，比马格鲁单抗（BYM338）阻断激活素受体对骨愈合是否有不利影响？
Calcif Tissue Int. 2016 Sep;99(3):310-21. doi: 10.1007/s00223-016-0148-0. Epub 2016 May 11.
8
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
9
The COPD Pipeline XXXI.慢性阻塞性肺疾病药物研发进展第三十一期
Chronic Obstr Pulm Dis. 2016 Apr 18;3(2):589-593. doi: 10.15326/jcopdf.3.2.2016.0140.
10
Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.三联吸入疗法与双联吸入疗法治疗中重度慢性阻塞性肺疾病：一项随机对照试验的系统评价和荟萃分析
Clin Respir J. 2019 Jul;13(7):413-428. doi: 10.1111/crj.13026. Epub 2019 May 2.
引用本文的文献
1
CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.CHF6297：一种新型强效选择性p38丝裂原活化蛋白激酶抑制剂，具有强大的抗炎活性，适用于作为干粉进行吸入式肺部给药。
Front Pharmacol. 2024 Mar 14;15:1343941. doi: 10.3389/fphar.2024.1343941. eCollection 2024.
本文引用的文献
1
A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.一项关于长效抗胆碱能药物/长效β2受体激动剂双重支气管扩张治疗稳定期慢性阻塞性肺疾病的系统评价与荟萃分析
Chest. 2016 May;149(5):1181-96. doi: 10.1016/j.chest.2016.02.646. Epub 2016 Feb 26.
2
Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.用于评估对p38丝裂原活化蛋白激酶抑制剂BCT197耐受性的群体药代动力学-药效学模型
CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700. doi: 10.1002/psp4.12037. Epub 2015 Nov 9.
3
Cystic fibrosis microbiology: Advances in antimicrobial therapy.囊性纤维化微生物学：抗菌治疗的进展
J Cyst Fibros. 2015 Sep;14(5):551-60. doi: 10.1016/j.jcf.2015.02.005. Epub 2015 Feb 28.
4
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.ActRIIB 拮抗作用逆转癌症恶病质和肌肉减少症导致生存期延长。
Cell. 2010 Aug 20;142(4):531-43. doi: 10.1016/j.cell.2010.07.011.
Zotero 插件